Biopharma Investor ESG Communications Initiative
“A confirmation that we are on track with our strategic thinking on ESG.”
- Biopharma
The Biopharma Investor ESG Communications Initiative was set up to address the common interest of leading biopharma companies and investors in achieving more effective and efficient communications about the sector’s environmental, social, and governance (ESG) topics.
The Challenge
Biopharma and investors alike recognize challenges in deciding which biopharma environmental, social and governance topics are most relevant due to several factors:
- Fatigue over proliferation of competing ESG ratings, standards, and frameworks
- Confusion over score divergence and perceived transparency of ESG ratings
- Lack of consensus about effective and efficient communications
Consensus Oriented Dialog
The Initiative facilitates a sector-focused direct dialog between biopharma and investors, complemented by engagement with key sector stakeholders. The conversations seek to build consensus on what ESG information from biopharma companies should be communicated to the capital markets, and how it could be most usefully structured.
Over 150 executives from 28 biopharma and 32 investor companies have engaged in discussions, and workshops since 2018.
Forward-looking Guidance
The Biopharma Investor ESG Communications Guidance (April 2020 version) distills the consensus from two years of biopharma and investor engagement.
Intended as a resource for both biopharma and investors, it provides a high-level roadmap that identifies the biopharma ESG topics of shared priority and gives recommendations on how to communicate that can be adapted to a company’s own strategy business model and readiness.
Initiative Partners, Participants, and Sponsors
Publications
“Senior Management trusts the Guidance because it has been tested with peers and investors.”
-Biopharma
Biopharma Investor ESG Communications Guidance 3.0
Available for participants and contributors only – please contact us if you are interested.
Biopharma Investor ESG Communications Guidance
April 2020
Integrating Sustainability and Long Term Planning for the Biopharma Sector
Myrto Kontaxi, BSRT, and Brian Tomlinson, CECP, on integrating CECP’s Long-Term Plan Framework and the Biopharma Investor ESG Communications Guidance to support sustainable long-term strategy for biopharma.
Ongoing Dialogs
“Since the Initiative launched, more than 100 executives from biopharma and investor companies have engaged in high-value direct dialogs. Discussions with key stakeholder groups are ongoing, and the circle of contributors is expanding.”
BSRT Investor Network Participants
